The Evolution of Antisense Oligonucleotide Chemistry—A Personal Journey
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Evolution of Antisense Oligonucleotide Chemistry—A Personal Journey
Authors
Keywords
-
Journal
Biomedicines
Volume 9, Issue 5, Pages 503
Publisher
MDPI AG
Online
2021-05-05
DOI
10.3390/biomedicines9050503
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma
- (2021) Cara Haymaker et al. Cancer Discovery
- Phosphorothioate modified oligonucleotide–protein interactions
- (2020) Stanley T Crooke et al. NUCLEIC ACIDS RESEARCH
- RNA Therapeutics Are Stepping Out of the Maze
- (2020) Sudhir Agrawal TRENDS IN MOLECULAR MEDICINE
- Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
- (2019) Jinkuk Kim et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy
- (2018) Daqing Wang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Sa1757 Targeting Innate Immune Receptors to Treat Inflammatory Bowel Disease: Preclinical Activity of IMO-9200, an Antagonist of TLRS 7, 8, and 9 in Mouse Models of Colitis
- (2015) Fugang Zhu et al. GASTROENTEROLOGY
- A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice
- (2013) Fu-Gang Zhu et al. AUTOIMMUNITY
- A Toll-Like Receptor 7, 8, and 9 Antagonist Inhibits Th1 and Th17 Responses and Inflammasome Activation in a Model of IL-23-Induced Psoriasis
- (2013) Weiwen Jiang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9
- (2013) Ekambar R. Kandimalla et al. NUCLEIC ACIDS RESEARCH
- Immune-Stimulatory Dinucleotide at the 5′-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses
- (2013) Mallikarjuna R. Putta et al. ACS Medicinal Chemistry Letters
- Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo
- (2012) Tao Lan et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Novel Oligonucleotides Containing Two 3′-Ends Complementary to Target mRNA Show Optimal Gene-Silencing Activity
- (2011) Lakshmi Bhagat et al. JOURNAL OF MEDICINAL CHEMISTRY
- A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine
- (2010) Antonella Conforti et al. VACCINE
- Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8
- (2009) Tao Lan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Peptide Conjugation at the 5′-End of Oligodeoxynucleotides Abrogates Toll-Like Receptor 9-Mediated Immune Stimulatory Activity
- (2009) Mallikarjuna Reddy Putta et al. BIOCONJUGATE CHEMISTRY
- Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8
- (2009) Tao Lan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action
- (2009) V. Damiano et al. CLINICAL CANCER RESEARCH
- Modifications Incorporated in CpG Motifs of Oligodeoxynucleotides Lead to Antagonist Activity of Toll-like Receptors 7 and 9
- (2009) Dong Yu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Toll-like Receptor 7 Selective Synthetic Oligoribonucleotide Agonists: Synthesis and Structure−Activity Relationship Studies
- (2009) Tao Lan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Oligodeoxyribonucleotide-Based Antagonists for Toll-Like Receptors 7 and 9
- (2008) Daqing Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started